RxDoctor Payments Data

Bhavik Khatri, DO

Cardiovascular Disease · Fresno, CANPI 1457643298

Payments from drug & device makers

$25,914in general payments, 2019–2025

Across 856 payments — averaging $30.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$4K
  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Esperion Therapeutics, Inc.$1K
  • Novo Nordisk$1K
  • plus $15K from 41 others

What the payments were for

  • Speaking & faculty fees$2,82011%
  • Food & beverage$23,08489%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,914 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$391,558
Medicare patients
676
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$389,130
VyndamaxTafamidis13$286,572
FarxigaDapagliflozin Propanediol199$221,023
JardianceEmpagliflozin121$183,138
XareltoRivaroxaban73$95,179
CamzyosMavacamten13$88,024
EntrestoSacubitril/Valsartan61$75,411
MultaqDronedarone Hcl21$48,531
OzempicSemaglutide30$28,098
Repatha SureclickEvolocumab40$22,813
BrilintaTicagrelor17$14,276
DapagliflozinDapagliflozin Propanediol13$10,154
Metoprolol Succinate371$5,116
Rosuvastatin Calcium231$4,740
Icosapent Ethyl11$4,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$667$675,702335 claims
AstraZenecaFarxiga, Brilinta$1,743$235,299216 claims
Boehringer IngelheimJardiance$1,840$183,138121 claims
Johnson & JohnsonXarelto$1,096$95,17973 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,406$88,02413 claims
NovartisEntresto$1,245$75,41161 claims
Sanofi-aventis U.S. LLCMultaq$3,523$48,53121 claims
Novo NordiskOzempic$1,295$28,09830 claims
Arbor Pharmaceuticals, Inc.Edarbi$23$4,04715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →